During the study, participants will receive semaglutide for 25 weeks, followed by one week where pramlintide is added to the treatment. Throughout the study, participants will undergo various tests to measure how their body responds to food and how quickly their stomach processes it. One of these tests involves taking paracetamol, a common pain reliever, to measure how fast food moves through the stomach.

The researchers will measure changes in how much food participants eat during test meals and track weight loss throughout the study. They will also monitor how participants feel about their appetite and fullness levels. The study will last approximately 26 weeks, during which the medications will be given through subcutaneous injection under the skin.

The purpose of the study is to see if using GLP-1 receptor agonists right after a kidney transplant can prevent the development of diabetes in people who are at high risk. Participants in the study will receive either the medication or a placebo. The study will follow participants for a period of up to 12 months, with regular check-ups to monitor their health and any changes in their condition. During these visits, various health indicators such as blood sugar levels, weight, and kidney function will be assessed.

This trial aims to provide valuable information on whether early treatment with Trulicity can help prevent diabetes in kidney transplant recipients. The study will also look at other health factors, including the need for additional diabetes medications, changes in body weight, and overall kidney health. The results could lead to better management strategies for preventing diabetes in people who have undergone a kidney transplant.

The purpose of the study is to see if treatment with Trulicity can help reverse metabolic syndrome in these patients. The study will last for up to six months, during which participants will receive the medication as an injection. The researchers will check the participants’ health status at three and six months to see if there are improvements in their metabolic syndrome. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, the researchers will monitor various health indicators, such as blood sugar levels and body weight, to assess changes in the participants’ conditions. They will also keep track of any side effects, such as nausea, diarrhea, or headaches, and any changes in insulin sensitivity, which is how well the body responds to insulin. The study aims to provide valuable information on whether Trulicity can be an effective preventive treatment for diabetes in patients awaiting kidney transplants.